Puma Biotechnology (PBYI) CEO sells 44,058 shares under 10b5-1 plan

Rhea-AI Filing Summary

Puma Biotechnology President and CEO Alan H. Auerbach reported an open-market sale of 44,058 shares of common stock at $8.263 per share on July 6, 2026. After this transaction, he still directly holds 7,261,671 shares, suggesting it represents a small portion of his stake. The sale was executed under a pre-established Rule 10b5-1(c) sell-to-cover program adopted on December 17, 2020, indicating it was part of a pre-planned trading arrangement.

Insider Trade Summary 10b5-1

Net Seller: 44,058 shares ($364,051)

Net Sell 1 txn

Insider AUERBACH ALAN H

Role President and CEO

Sold 44,058 shs ($364K)

Type	Security	Shares	Price	Value
Sale	Common Stock	44,058	$8.263	$364K

Holdings After Transaction: Common Stock — 7,261,671 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 44,058 shares Sale price: $8.263 per share Shares held after sale: 7,261,671 shares +2 more

5 metrics

Shares sold 44,058 shares Open-market sale on July 6, 2026

Sale price $8.263 per share Price for common stock in reported sale

Shares held after sale 7,261,671 shares Direct ownership following the transaction

Net buy/sell direction Net sell of 44,058 shares TransactionSummary netBuySellShares

10b5-1 plan adoption date December 17, 2020 Rule 10b5-1(c) sell-to-cover program

Key Terms

open-market sale, Rule 10b5-1(c), Form 4, transaction code "S"

4 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Rule 10b5-1(c) regulatory

"referenced 10b5-1(c) sell to cover program is: 12-17-2020"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

transaction code "S" regulatory

"transaction_code: "S" for sale in open market"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/08/2026 - 08:21 PM Accepted by SEC EDGAR 07/08/2026 - 08:21 PM Learn about SEC filing dates

FAQ

What insider transaction did PBYI report for Alan H. Auerbach?

Puma Biotechnology reported that CEO Alan H. Auerbach sold 44,058 shares of common stock at $8.263 per share. After this open-market sale, he continued to hold 7,261,671 shares directly, indicating he retains a very large position in the company.

At what price did Puma Biotechnology (PBYI) shares sell in this Form 4?

The reported sale was executed at an average price of $8.263 per Puma Biotechnology share. The transaction involved 44,058 common shares in an open-market sale, as disclosed in the Form 4 insider trading report filed for CEO Alan H. Auerbach.

How many Puma Biotechnology shares does the CEO hold after this Form 4 sale?

Following the reported sale, CEO Alan H. Auerbach directly holds 7,261,671 Puma Biotechnology common shares. This remaining balance, disclosed in the Form 4, shows that the 44,058 shares sold represent only a small fraction of his total ownership position.

Was the PBYI CEO’s share sale made under a Rule 10b5-1 plan?

Yes. The footnote states the sale was under a Rule 10b5-1(c) sell-to-cover program adopted on December 17, 2020. Such pre-arranged trading plans are designed to schedule transactions in advance, reducing the significance of their specific timing.

Is the Puma Biotechnology Form 4 transaction a buy or a sell?

The Form 4 reports a sell transaction by CEO Alan H. Auerbach. It records an open-market sale of 44,058 common shares at $8.263 per share, classified with transaction code “S” for sale in the insider trading data.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AUERBACH ALAN H

(Last) (First) (Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BLVD., SUITE 1700

(Street)

LOS ANGELES CALIFORNIA 90024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/06/2026		S(1)		44,058	D	$8.263	7,261,671	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Adoption date of referenced 10b5-1(c) sell to cover program is: 12-17-2020.

	/s/ Gordon Esplin as attorney-in-fact for Alan H. Auerbach	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)